Candriam Equities L Biotechnology Class Z USD CapRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 17.5 | -0.1 | 12.8 | 2.9 | 10.5 | |
+/-Cat | -8.4 | 8.9 | 20.6 | 4.2 | 9.1 | |
+/-B’mrk | -15.4 | -0.4 | 10.3 | -4.4 | 4.7 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 21/11/2024 | USD 2424.42 | |
Day Change | 0.34% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU0240982651 | |
Fund Size (Mil) 21/11/2024 | USD 1411.83 | |
Share Class Size (Mil) 21/11/2024 | USD 18.26 | |
Max Initial Charge | - | |
Ongoing Charge 02/07/2022 | 0.20% |
Investment Objective: Candriam Equities L Biotechnology Class Z USD Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Linden Thomson 29/02/2024 | ||
Rudi Van den Eynde 06/04/2000 | ||
Click here to see others | ||
Inception Date 05/08/2015 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Candriam Equities L Biotechnology Class Z USD Cap | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Regeneron Pharmaceuticals Inc | Healthcare | 6.42 |
Amgen Inc | Healthcare | 5.97 |
Gilead Sciences Inc | Healthcare | 5.17 |
Alnylam Pharmaceuticals Inc | Healthcare | 5.03 |
Vertex Pharmaceuticals Inc | Healthcare | 4.82 |
Increase Decrease New since last portfolio | ||
Candriam Equities L Biotechnology Class Z USD Cap |